Security
Trinity Biotech plc American Depositary Shares · TRIB
TRIBNASDAQotherCurrentCIK 888721Updated Oct 6, 2026
TRIB price & chart
Loading TradingView…
NASDAQ:TRIB on TradingView ↗About the company
We are a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. We develop, acquire, manufacture and market diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. We intend to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | Q2 2018 | Q2 2017 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||
| Profit or LossUSD | 594,000Source | 902,000Source | -31,216,000Source | -36,868,000Source | -41,002,000Source | 929,000Source |
| Additional Financial Items | ||||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | — | 10,000Source | -198,000Source | 61,000Source | 0Source |
| AdjustmentsForFinanceCostsUSD | — | — | 9,565,000Source | 11,053,000Source | 24,745,000Source | 7,097,000Source |
| AdjustmentsForFinanceIncomeUSD | — | — | 0Source | 1,171,000Source | 303,000Source | 1,223,000Source |
| AdjustmentsForIncomeTaxExpenseUSD | — | — | 486,000Source | -59,000Source | -192,000Source | -167,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 329,000Source | 130,000Source | 1,316,000Source | 2,069,000Source | 1,755,000Source | 1,100,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | 1,010,000Source | 238,000Source | -76,000Source | -251,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | -30,000Source | 62,000Source | -1,010,000Source | -312,000Source | 15,000Source | -1,619,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | — | — | 8,000Source | 8,000Source | 1,293,000Source | 3,996,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | — | 0Source | 0Source | 11,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | — | — | 0Source | 0Source | 2,000Source | 1,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | 2,503,000Source | 2,318,000Source | 2,761,000Source | 2,939,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | 0Source | 0Source | 1,764,000Source |
| ProceedsFromIssuingSharesUSD | — | — | 7,391,000Source | 0Source | 25,336,000Source | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 9,659,000Source | 1,901,000Source | 4,876,000Source | 6,879,000Source |
| IncreaseDecreaseInWorkingCapital | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q2 2018 | Q2 2017 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | 7,358,000Source | 7,561,000Source | 28,815,000Source | 31,152,000Source | 29,166,000Source | 24,683,000Source |
| Total RevenueUSD | 25,002,000Source | 25,448,000Source | 61,555,000Source | 56,832,000Source | 74,779,000Source | 92,965,000Source |
| Additional Financial Items | ||||||
| ApplicableTaxRatenumber | — | — | 0.13Source | 0.13Source | 0.13Source | 0.13Source |
| AuditorsRemunerationForTaxServicesUSD | — | — | 1,082,000Source | 861,000Source | 888,000Source | 549,000Source |
| AverageEffectiveTaxRatenumber | — | — | -0.02Source | -0Source | -0Source | -0.24Source |
| CurrentTaxExpenseIncomeUSD | — | — | 21,000Source | 0Source | -331,000Source | -511,000Source |
| DeferredTaxExpenseIncomeUSD | — | — | 201,000Source | -323,000Source | 83,000Source | 37,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | — | — | -683,000Source | 323,000Source | -83,000Source | 37,000Source |
| DepreciationAndAmortisationExpenseUSD | — | — | 204,000Source | 0Source | — | 39,000Source |
| DepreciationRightofuseAssetsUSD | — | — | — | 0Source | 34,000Source | 27,000Source |
| EmployeeBenefitsExpenseUSD | — | — | 30,152,000Source | 28,841,000Source | 28,025,000Source | 30,686,000Source |
| FinanceCostsUSD | 1,158,000Source | 1,169,000Source | 9,565,000Source | 11,053,000Source | 24,745,000Source | 7,097,000Source |
| FinanceIncomeUSD | 196,000Source | 196,000Source | 0Source | 1,171,000Source | 303,000Source | 1,223,000Source |
| GrossProfitUSD | 10,808,000Source | 10,819,000Source | 21,441,000Source | 19,450,000Source | 22,048,000Source | 38,077,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 1,596,000Source | 5,833,000Source | 4,624,000Source | 3,853,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | — | — | 1,408,000Source | 11,105,000Source | 5,839,000Source | 6,944,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 158,000Source | 176,000Source | 486,000Source | -59,000Source | -192,000Source | -178,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | 592,000Source | 624,000Source | 657,000Source | 815,000Source |
| OtherIncomeUSD | — | — | 40,000Source | 138,000Source | 0Source | 0Source |
| OtherOperatingIncomeExpenseUSD | 24,000Source | 26,000Source | -1,787,000Source | 141,000Source | 343,000Source | 4,672,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | — | — | 451,000Source | 508,000Source | 352,000Source | 352,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | — | — | 451,000Source | 507,609Source | 352,000Source | 352,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | — | — | -31,789,000Source | -24,018,000Source | -41,009,000Source | 875,000Source |
| ProfitLossBeforeTaxUSD | 764,000Source | 859,000Source | -30,730,000Source | -36,927,000Source | -41,194,000Source | 751,000Source |
| ProfitLossFromOperatingActivitiesUSD | 1,726,000Source | 1,832,000Source | -21,165,000Source | -27,045,000Source | -16,752,000Source | 6,625,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,419,000Source | 1,322,000Source | 4,543,000Source | 4,379,000Source | 4,138,000Source | 4,497,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | — | — | 0.07Source | -0.08Source | -0.08Source | -0Source |
| BasicEarningsLossPerShare | —Source | —Source | — | — | — | — |
| DilutedEarningsLossPerShare | —Source | —Source | — | — | — | — |
Offerings
Registration 333-293717
Registration 333-295842
Registration 333-295846
Registration 333-292753
Filing attachments
ex991_1.htm · 6-K · 2026-09-09
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Paul Murphy Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure - Trinovium to supply RTI with advan…
Read attachment ↗ex992_2.htm · 6-K · 2026-09-08
Exhibit 99.2 TRINITY BIOTECH PLC (Incorporated and registered in Ireland with registered number 183476) 4 September 2026 Dear Shareholder, Annual General Meeting of Trinity Biotech plc (the “Company”) The board of directors (the “Board”) of the Company encloses notice of an annual general meeting of the Company, to be held at the Company’s registered office at IDA Business Park, Bray, County Wicklow, Ireland, A98 H5C8, on 30 September 2026 at 10:00 am (the “AGM”). Business of Annual Gener…
Read attachment ↗ex991_1.htm · 6-K · 2026-08-28
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Paul Murphy Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update - Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - - P…
Read attachment ↗ex991_1.htm · 6-K · 2026-08-17
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Paul Murphy Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure - Collaboration with leading hyperscale …
Read attachment ↗ex991_1.htm · 6-K · 2026-08-14
Exhibit 99.1 Contact: Trinity Biotech plc RedChip Companies Inc. Paul Murphy Dave Gentry, CEO (353)-1-2769800 (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement - Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company…
Read attachment ↗ex992_2.htm · 6-K · 2026-08-14
Exhibit 99.2 Execution Version Limited waiver and fourth amendment to sixth amended and restated credit agreement and guaranty This Limited Waiver and Fourth Amendment to Sixth Amended and Restated Credit Agreement and Guaranty (herein, this “Fourth Amendment”) is entered into as of August 12, 2026, by and among TRINITY BIOTECH, INC., a Delaware corporation (“U.S. Holdings”), CLARK LABORATORIES, INC. (d/b/a Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), BIOPOOL U.S., INC., a D…
Read attachment ↗